-
This is a good deal for developing nations getting drugs at an affordable price. This makes Johnson and Johnson the first pharma company to license generic copies before approval is even given. J and J licensed the drug for use in 48 countries listed as least developed countries to include...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Sun, Jan 30 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Pills, FDA, Generic Drugs, Patents, Johnson and Johnson, AIDS, licence, Tibotec, regulators
-
Well the patients in the US have to wait a little longer and it is amazing that in Europe as the title suggests has generics available. In May of 2010 Plavix was given a ruling by the FDA to establish a black box warning too. FDA Gives Plavix New Box Warning Relating to Metabolization in...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Jan 26 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Pills, FDA, Generic Drugs, Marketing, Patents, Europe, Plavix, Sanofi-Aventis, expire, Bristol-Myers Squibb
-
For a little history here on ED drugs, not too long ago the US Copyright office declined to give Pfizer the trademark on Viagra, saying it was too close to Horney goat weed, and hey if nothing else you have to love the name of this herb. I had actually mentioned this product as one of the alternatives...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Mon, Jun 21 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Medical Devices, Pharma, Viagra, R and D, Patents, ED, erectile dysfunction, healthare, Goats, Horny Goat Weed, Cialis, Coffee, court cases, herb, trademark
-
This is interesting and a deal was made here so Teva has a 180 day exclusive. On one hand we have Teva in court with Merck over Singulair and on the other hand here, they get a deal. Teva is probably the most aggressive pharma company today with challenging patents. Merck and Singulair –...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Apr 7 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Pharma, Hypertension, Generic Drugs, Merck, Patents, Teva, Intellutual property, Cozaar, Hyzaar
-
Back when this patent was given it was done to protect the research and development areas to recoup their investments, but today as things are changing rapidly, not only in genomics, but in medical devices and with drugs too, the long standing patent protections are coming under fire. If you read here...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Mon, Apr 5 2010
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, Genomics, healthcare, Genes, Breast Cancer, Economy, Patents, blood test, Myriad, legal cases, 60 Minutes, BRACanalysis
-
The FDA has given Teva tentative approval to begin selling a generic version in 2012. Teva states the patent for 2019 is invalid and a generic product will not .png?imgmax=800" width="153" height="59" alt="" />infringe. This goes back to 2004 when Teva notified Pfizer of their intention. ...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Apr 2 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Medical Devices, Pharma, Viagra, R and D, Patents, ED, erectile dysfunction, healthare, Goats, Horny Goat Weed, Cialis, Teva, Coffee, court cases, herb, trademark
-
Here’s some more healthcare money being spent on legal suits over ED drugs. You know if pharma keeps up with all these extensive legal battles it might begin to start depleting some profits and of course it keeps the cost up there for us. There’s an appeal process too and this goes back to...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Feb 16 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Medical Devices, Pharma, Viagra, R and D, Patents, ED, erectile dysfunction, healthare, Goats, Horny Goat Weed, Cialis, Coffee, court cases, herb, trademark
-
If you are not aware this is the treatment used for Herpes and all of this began back in 2005, so how long these legal issues go on and all the money spent, which ends up coming down the line to use as consumers in what we pay for drugs. I think these long legal court battles that keep the price...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Mon, Feb 15 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, FDA, Patents, Teva, Novartis, drugs discounts, Famvir
-
One comment I have to make here is that this certainly doesn’t help the cost of stents for people who need the medical side of this. This is the big part of healthcare costs that does nothing for the patients, but rolls up big bank rolls. This also brings to the forefront the growing lack of patience...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Mon, Feb 1 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Cardiology, Stents, Patents, Johnson and Johnson Development Corporation, Boston Scientific, Legal stents, stupid lawsuits
-
A disappointment for Merck and this is not the only patent tied up in the legal system today, Singulair is another one where the patent is being questioned. Merck plans to appeal the case according to the article, ho hum, more legal cases to drive up the cost of the medicine we need. BD ...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Jan 26 2010
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, healthcare, Pharma, FDA, Generic Drugs, Merck, Patents, Amgen, Intellectual property, Teva, legal cases
-
I can see both sides of this with the demand for cheaper drugs and the need for the company who developed them to be protected so they can recoup their expenses. We have couple other issues involved here too in the fact that producing a drug due to technology may not take as much time as it did...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Jan 15 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Generic Drugs, Politics, Obama, Patents, Intellectual property, Pricing, healthcare reform, biologic drugs
-
According to this article from the New York Times, only 22 percent of prescription spending is the US is spent on generic drugs, the rest is name brands prescribed by physicians. Major drug companies cut deals with generic manufacturers granting who can market them and I see this as having a pricing...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Jan 13 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Prescriptions, Generic Drugs, Merck, Politics, Patents, Amgen, Teva, FTC, heatlhcare reform, anti-trust, intellctual property, drug deals
-
One more drug that is coming off patent and Ranbaxy in New Jersey will have a 180 day exclusive for marketing. Valtrex now having a generic should be cheaper and more affordable real soon. Ranbaxy is a division of Daiichi Sankyo in Japan. For a little history on the purchase of Ranbaxy, formerly...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Sun, Nov 29 2009
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, FDA, Ranbaxy, Patents, GlaxoSmithKline, herpes, shingles, Valtrex, valacyclovir
-
E-Zassi has rolled out a standalone module of their InnoVision software – the US Regulatory Calculator. This new tool allows a user to generate a report in less than 10 minutes that documents a potential predicate FDA regulation no., product code and the classification & regulatory pathway associated...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Tue, Oct 20 2009
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, healthcare, Medical Devices, FDA, Science, Patents, Research and Development, Intellectual property, Web 2.0, collaboration, e-Zassi
-
This is something else from the old methodologies of doing business and it’s not going away any time soon, but are there lines crossed when curing disease gets in the way of a company maintaining and not sharing a patent? This really pretty much opens that discussion. In working with today...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Sat, Oct 10 2009
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, DNA, Genomics, Genes, Biotech, Heatlhcare, Patents, Lab Tests, Algorithms, Intelligent Property, treatments, screening, disease cure, royalties